Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population
AZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the preexposure prophylaxis of COVID-19 and for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of severe COVID-19. Thus, the aim of the present...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Case Reports in Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2024/9163490 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544475693449216 |
|---|---|
| author | Constant Gillot Jean-Louis Bayart Vincent Maloteau Jean-Michel Dogné Jonathan Douxfils Julien Favresse |
| author_facet | Constant Gillot Jean-Louis Bayart Vincent Maloteau Jean-Michel Dogné Jonathan Douxfils Julien Favresse |
| author_sort | Constant Gillot |
| collection | DOAJ |
| description | AZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the preexposure prophylaxis of COVID-19 and for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of severe COVID-19. Thus, the aim of the present study is to evaluate the neutralizing capacity of tixagevimab and cilgavimab across different SARS-CoV-2 variants in two patients who received AZD7442 for immunoprophylaxis. A cohort of subjects (n = 45) who had received the BNT162b2 mRNA COVID-19 vaccine has been included to compare these two preventive strategies. Neutralizing antibody (NAb) titers against several variants were assessed against the wild-type, alpha, beta, gamma, delta, omicron BA.5, and XBB.1.5 variants. Binding antibodies have also been measured. NAbs T1/2 for AZD7442 was 8.1 days (95% CI: 5.1–19.5 days) and was 11.8 days (95% CI: 7.9–23.7 days) for the primo-vaccination cohort. The time to reach neutralization negativity was 108.3 days (95% CI: 66.9–130.7) for AZD7442 compared to 95.4 days (95% CI: 31.0–119.7 days) for the primo-vaccination cohort. The time to reach NAbs’ negativity differs between variants with the maximum value obtained for alpha (i.e., 101.1 days (95% CI: 30.0–135.4 days)) and the minimum obtained for beta (i.e., 61.2 days (95% CI: 37.8–77.1 days)). Our results reinforce the need of reviewing the use of AZD7442 in relation to variants of concern and potentially adapting its administration schedule. AZD7442 could be indicated for short-term prophylaxis in frail patients who may be acutely exposed to SARS-CoV-2. |
| format | Article |
| id | doaj-art-48187b9f35a94c59a805d7f0372ec0ca |
| institution | Kabale University |
| issn | 2090-6633 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Infectious Diseases |
| spelling | doaj-art-48187b9f35a94c59a805d7f0372ec0ca2025-02-03T10:18:13ZengWileyCase Reports in Infectious Diseases2090-66332024-01-01202410.1155/2024/9163490Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated PopulationConstant Gillot0Jean-Louis Bayart1Vincent Maloteau2Jean-Michel Dogné3Jonathan Douxfils4Julien Favresse5Clinical Pharmacology and Toxicology Research UnitDepartment of Laboratory MedicineDepartment of PharmacyClinical Pharmacology and Toxicology Research UnitClinical Pharmacology and Toxicology Research UnitClinical Pharmacology and Toxicology Research UnitAZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the preexposure prophylaxis of COVID-19 and for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of severe COVID-19. Thus, the aim of the present study is to evaluate the neutralizing capacity of tixagevimab and cilgavimab across different SARS-CoV-2 variants in two patients who received AZD7442 for immunoprophylaxis. A cohort of subjects (n = 45) who had received the BNT162b2 mRNA COVID-19 vaccine has been included to compare these two preventive strategies. Neutralizing antibody (NAb) titers against several variants were assessed against the wild-type, alpha, beta, gamma, delta, omicron BA.5, and XBB.1.5 variants. Binding antibodies have also been measured. NAbs T1/2 for AZD7442 was 8.1 days (95% CI: 5.1–19.5 days) and was 11.8 days (95% CI: 7.9–23.7 days) for the primo-vaccination cohort. The time to reach neutralization negativity was 108.3 days (95% CI: 66.9–130.7) for AZD7442 compared to 95.4 days (95% CI: 31.0–119.7 days) for the primo-vaccination cohort. The time to reach NAbs’ negativity differs between variants with the maximum value obtained for alpha (i.e., 101.1 days (95% CI: 30.0–135.4 days)) and the minimum obtained for beta (i.e., 61.2 days (95% CI: 37.8–77.1 days)). Our results reinforce the need of reviewing the use of AZD7442 in relation to variants of concern and potentially adapting its administration schedule. AZD7442 could be indicated for short-term prophylaxis in frail patients who may be acutely exposed to SARS-CoV-2.http://dx.doi.org/10.1155/2024/9163490 |
| spellingShingle | Constant Gillot Jean-Louis Bayart Vincent Maloteau Jean-Michel Dogné Jonathan Douxfils Julien Favresse Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population Case Reports in Infectious Diseases |
| title | Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population |
| title_full | Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population |
| title_fullStr | Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population |
| title_full_unstemmed | Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population |
| title_short | Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population |
| title_sort | evaluation of neutralizing capacity of tixagevimab plus cilgavimab azd7442 against different sars cov 2 variants a case report study with comparison to a vaccinated population |
| url | http://dx.doi.org/10.1155/2024/9163490 |
| work_keys_str_mv | AT constantgillot evaluationofneutralizingcapacityoftixagevimabpluscilgavimabazd7442againstdifferentsarscov2variantsacasereportstudywithcomparisontoavaccinatedpopulation AT jeanlouisbayart evaluationofneutralizingcapacityoftixagevimabpluscilgavimabazd7442againstdifferentsarscov2variantsacasereportstudywithcomparisontoavaccinatedpopulation AT vincentmaloteau evaluationofneutralizingcapacityoftixagevimabpluscilgavimabazd7442againstdifferentsarscov2variantsacasereportstudywithcomparisontoavaccinatedpopulation AT jeanmicheldogne evaluationofneutralizingcapacityoftixagevimabpluscilgavimabazd7442againstdifferentsarscov2variantsacasereportstudywithcomparisontoavaccinatedpopulation AT jonathandouxfils evaluationofneutralizingcapacityoftixagevimabpluscilgavimabazd7442againstdifferentsarscov2variantsacasereportstudywithcomparisontoavaccinatedpopulation AT julienfavresse evaluationofneutralizingcapacityoftixagevimabpluscilgavimabazd7442againstdifferentsarscov2variantsacasereportstudywithcomparisontoavaccinatedpopulation |